Fiera Capital Corp Cuts Position in Immunocore Holdings plc (NASDAQ:IMCR)

Fiera Capital Corp lowered its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 3.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 845,732 shares of the company’s stock after selling 29,861 shares during the period. Fiera Capital Corp’s holdings in Immunocore were worth $26,328,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC increased its stake in Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC acquired a new position in shares of Immunocore during the 3rd quarter worth $218,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Immunocore by 69.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after buying an additional 3,053 shares in the last quarter. DNB Asset Management AS increased its holdings in Immunocore by 35.0% during the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after acquiring an additional 1,868 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Immunocore during the second quarter worth about $303,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IMCR. Needham & Company LLC lowered their price target on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday. Morgan Stanley dropped their price target on Immunocore from $80.00 to $74.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. UBS Group initiated coverage on Immunocore in a research report on Thursday, October 24th. They set a “sell” rating and a $24.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $73.73.

Immunocore Trading Up 1.1 %

IMCR stock opened at $34.69 on Friday. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The firm’s 50-day simple moving average is $32.66 and its 200 day simple moving average is $39.66. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The company had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.98% and a negative net margin of 15.87%. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.59) EPS. Analysts predict that Immunocore Holdings plc will post -1.71 EPS for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.